+7 (343) 270-75-00

          info@uphc.ru

News

At the end of the last year, Novouralsk-based Medsintez Plant turned 20 years old. Alexander Petrov, Chairman of the plant's Board of Directors, told Regions of Russia about the impressive successes that the company has achieved over the years and its ambitious plans for the future.

In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease. The preparations are available in the most convenient and familiar for patients dosage form – a disposable prefilled injection and have already been supplied to pharmacies.

Medsintez Plant LLC presented the latest biotechnological developments of pharmaceuticals at the largest international scientific and practical forum in the field of medicine and health care Russian Health Care Week — 2023 held from December 4 to December 8 in Moscow. The main purpose of the Forum is to facilitate the implementation of the national projects “Healthcare” and “Demography”, “Tourism and Hospitality Industry”, the federal project “Development of Medical Services Export”, as well as summarizing the results of the Year of Science and Technology in Medicine.

On September 27, as part of the business program of the GMP conference with international participation, Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, took part in a Plenary Session on the issues of regulating the circulation of medicines in Russia and the EAEU, developing import independence, and increasing export potential. The session was attended by representatives of the Ministry of Industry and Trade of the Russian Federation, the Minister of Health of the Republic of Nicaragua, the WHO Representative in Russia, a Representative of the Serbian Ministry of Health and other Russian and foreign experts. Mr. Petrov spoke about the problems that Russian pharmaceutical companies face when entering international markets and suggested possible solutions.

Dizet Plant LLC

Dizet Plant LLC specializes in manufacturing medical equipment and medical devices for the dialysis care. The plant runs Russia's only line, which produces domestic artificial kidney machines «Malachite», as well as hospital water treatment systems, automatic concentrate supply systems as well as dry and liquid dialysis concentrates. The technologies were developed by Ural scientists and nephrologists. The company manufactures import-substituting products, thus making life-saving treatment technologies closer to patients.

The «Malachite» machines are based on the technology used in similar products of NIPRO (Japan). 

They are used for extracorporeal blood purification by membrane dialysis with ultrafiltration in order to clear toxic metabolic products from the body and normalize water and electrolyte disbalances. According to the Russian Dialysis Society, the average annual need for these new devices is 500 to 700 units. The Dizet Plant can produce up to 400 «Malachite» artificial kidney machines per year.

«Unona AQUA-01», the automated water treatment system for apparatus treatment dialysis is a whole complex of supporting systems for hemodialysis departments. Currently, Dizet is the only manufacturer in Russia that produces water treatment systems designed to provide purified water for dialysis and equipped with a final electrodeionization purification unit and a unit for chemical treatment of water distribution loops. The production technologies used are unique for both the Russian and international markets. To date, in the Russian Federation, about  20% of medical entities providing dialysis care are equipped with supporting system complexes manufactured by the Dizet Plant LLC.     

Stroyindustrii proezd 6 A, Novouralsk, Sverdlovsk region, Russia, 624130. 

Phone: 8-961-761-5556, 8-922-604-0180 

Email: zavoddizet@gmail.com